PriceTargets.com logo

Audentes Therapeutics - BOLD Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $23.00
  • Forecasted Upside: 108.52%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$11.03 As of 04/24/2024 01:00 AM ET
▲ +0.37 (3.47%)
Get New Audentes Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BOLD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BOLD

Analyst Price Target is $23.00
▲ +108.52% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Audentes Therapeutics in the last 3 months. The average price target is $23.00, with a high forecast of $25.00 and a low forecast of $20.00. The average price target represents a 108.52% upside from the last price of $11.03.

This chart shows the closing price for BOLD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Audentes Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/22/2024Piper SandlerInitiated CoverageOverweight$20.00N/A
4/22/2024GuggenheimInitiated CoverageBuy$24.00N/A
4/22/2024SVB LeerinkInitiated CoverageOutperform$25.00N/A
1/20/2020Chardan CapitalReiterated RatingHoldLow
12/16/2019MizuhoReiterated RatingHold$60.00Low
12/5/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$60.00Low
12/4/2019Chardan CapitalReiterated RatingBuy ➝ Neutral$60.00Low
12/4/2019SVB LeerinkDowngradeOutperform ➝ Hold$60.00Low
12/3/2019Wells Fargo & CompanyLower TargetOutperform$20.00 ➝ $19.00N/A
12/3/2019Raymond JamesDowngradeOutperform ➝ Market PerformN/A
12/3/2019HC WainwrightDowngradeBuy ➝ Neutral$60.00N/A
12/3/2019MizuhoDowngradeBuy ➝ NeutralN/A
12/3/2019WedbushDowngradeOutperform ➝ Neutral$60.00N/A
12/3/2019CitigroupUpgradeSell ➝ Neutral$30.00 ➝ $60.00N/A
12/3/2019BMO Capital MarketsDowngradeOutperform ➝ Market Perform$47.00 ➝ $60.00N/A
12/3/2019Piper Sandler CompaniesDowngradeOverweight ➝ Neutral$55.00 ➝ $60.00N/A
12/3/2019Robert W. BairdUpgradeUnderperform ➝ NeutralN/A
12/3/2019GuggenheimDowngradeBuy ➝ NeutralN/A
11/27/2019Evercore ISIUpgradeIn-Line ➝ OutperformLow
11/22/2019Piper Sandler CompaniesReiterated RatingBuy$55.00Low
11/19/2019Evercore ISIUpgradeIn-Line ➝ Outperform$40.00High
11/11/2019Evercore ISIReiterated RatingHold$34.00High
11/8/2019HC WainwrightReiterated RatingBuy$48.00High
10/6/2019Chardan CapitalReiterated RatingBuy$50.00Low
10/2/2019Robert W. BairdInitiated CoverageUnderperform$10.00 ➝ $10.00Medium
9/3/2019Chardan CapitalBoost TargetBuy$40.00 ➝ $50.00High
8/7/2019MizuhoReiterated RatingBuy$45.00High
8/7/2019William BlairReiterated RatingHoldHigh
5/8/2019HC WainwrightSet TargetBuy$48.00Low
5/8/2019BMO Capital MarketsSet TargetBuy$47.00Low
4/26/2019HC WainwrightBoost TargetBuy ➝ Buy$44.00 ➝ $48.00Low
4/26/2019CitigroupDowngradeNeutral ➝ Sell$28.00 ➝ $32.00Low
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Audentes Therapeutics logo
Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $11.03
Low: $10.03
High: $11.21

50 Day Range

MA: $59.97
Low: $59.97
High: $59.97

52 Week Range

Now: $11.03
Low: $22.00
High: $60.00

Volume

158,747 shs

Average Volume

1,504,389 shs

Market Capitalization

$510.38 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.18

Frequently Asked Questions

What sell-side analysts currently cover shares of Audentes Therapeutics?

The following Wall Street sell-side analysts have issued reports on Audentes Therapeutics in the last twelve months: Guggenheim, Piper Sandler, and SVB Leerink LLC.
View the latest analyst ratings for BOLD.

What is the current price target for Audentes Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Audentes Therapeutics in the last year. Their average twelve-month price target is $23.00, suggesting a possible upside of 108.5%. SVB Leerink LLC has the highest price target set, predicting BOLD will reach $25.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $20.00 for Audentes Therapeutics in the next year.
View the latest price targets for BOLD.

What is the current consensus analyst rating for Audentes Therapeutics?

Audentes Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BOLD will outperform the market and that investors should add to their positions of Audentes Therapeutics.
View the latest ratings for BOLD.

What other companies compete with Audentes Therapeutics?

Other companies that are similar to Audentes Therapeutics include Alector, C4 Therapeutics, Taysha Gene Therapies, Fate Therapeutics and Humacyte. Learn More about companies similar to Audentes Therapeutics.

How do I contact Audentes Therapeutics' investor relations team?

Audentes Therapeutics' physical mailing address is 600 CALIFORNIA ST. 17TH FLOOR, SAN FRANCISCO CA, 94108. The biotechnology company's listed phone number is 415-818-1001 and its investor relations email address is [email protected]. The official website for Audentes Therapeutics is www.audentestx.com. Learn More about contacing Audentes Therapeutics investor relations.